Amlodipine, a dihydropyridine-type calcium channel blocker, lowers blood pressure by inhibiting calcium ion entry into vascular smooth muscle and cardiac muscle, with a more pronounced effect on blood vessels. This results in vasodilation and decreased peripheral vascular resistance.
Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), works by selectively blocking the binding of angiotensin II to the AT1 receptors in tissues such as vascular smooth muscle and the adrenal glands. This action inhibits vasoconstriction and aldosterone release without interfering with the ACE enzyme, allowing for effective blood pressure reduction without affecting bradykinin metabolism.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Abecab is prescribed for managing high blood pressure, either alone or with other antihypertensive medications. It may be used as an initial treatment in patients expected to require multiple agents to reach their target blood pressure. The decision to begin therapy with this combination should be individualized, considering factors such as the patient’s initial blood pressure levels, the target BP, and the likelihood of reaching the goal with combination therapy versus monotherapy. Blood pressure goals may differ depending on the individual's cardiovascular risk profile.
Combination antihypertensive agents (Calcium Channel Blocker + ARB).
Patients already taking Amlodipine and Olmesartan separately can switch to Abecab at equivalent doses. The combination may be adjusted by increasing the dose of either or both components as needed.
Initial dose: 5/20 mg once daily, which can be increased over 1–2 weeks to a maximum of 10/40 mg once daily.
Elderly patients (≥75 years): Since Amlodipine clearance is reduced, a starting dose of 2.5 mg is advisable, but the combination product does not allow for this lower dose. Therefore, starting therapy with Abecab is not advised in this age group.
Pediatrics: Safety and efficacy are not established.
Geriatrics: No notable differences in safety or efficacy compared to younger patients.
Renal impairment: No dedicated studies available.
Hepatic impairment: Not recommended as initial therapy.
Nonsteroidal anti-inflammatory drugs (NSAIDs), including COX-2 inhibitors, may reduce the antihypertensive effect of Olmesartan. Close monitoring of blood pressure, kidney function, and electrolytes is recommended when used in combination with NSAIDs or other agents that affect the renin-angiotensin system (RAS).
Concomitant use with Aliskiren is contraindicated in diabetic patients due to the risk of renal impairment, hypotension, and hyperkalemia.
Pregnancy Category D: Not recommended during the second or third trimester due to the risk of fetal harm or death. Discontinue immediately if pregnancy is detected.
Lactation: It is unclear whether the drug is secreted in human milk. A risk-benefit assessment should guide the decision to continue the drug or breastfeeding.
Use cautiously in the following cases:
Store at temperatures not exceeding 30°C. Protect from light and moisture. Keep out of children's reach.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.